Radiation Oncology

Lung Cancer

Appointment New Patient Appointment or 214-645-8525

UT Southwestern Medical Center’s lung cancer program includes a dedicated team that offers a level of expertise unmatched in Dallas and North Texas. We provide our patients with comprehensive, timely, and effective care.

Some of the most groundbreaking achievements in radiation therapy for lung cancer in the past decade have taken place at UT Southwestern. Our physicians have pioneered the use of stereotactic radiation to treat early-stage lung cancer, in some instances changing the medical standard of care for certain patient populations. 

Meet Our Team

Kenneth Westover, M.D., Ph.D.

Kenneth Westover, M.D., Ph.D., Chief of Lung Radiation Oncology Service

Shahed Badiyan, M.D.

Shahed Badiyan, M.D.

Anundip Gill, M.S.N., APRN, FNP-C

Anundip Gill, M.S.N., APRN, FNP-C

Yuanyuan Faith Zhang, M.D., Ph.D.

Yuanyuan Faith Zhang, M.D., Ph.D.

Educational Materials

Lung Clinical Trials

As one of the top academic medical centers in the country and the only National Cancer Institute-designated cancer center in North Texas, we lead and participate in a number of clinical trials aimed at improving the outcomes of patients with cancer. The Department of Radiation Oncology enrolls approximately 200 new patients in clinical trials each year. 

Clinical trials are critical in developing new therapies for cancer and can mean having access to new medication, groundbreaking research, and additional clinical care. Our clinical trials team is comprised of radiation oncologists, radiation biologists, clinical research coordinators, quality assurance coordinators, and clinical data specialists. 


STU 022015.069 (JoLT-Ca/STABLEMATES) A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High-Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC), the STABLEMATES Trial. Learn more about the JoLT-CA/STABLEMATES trial.

STU 2019.0858 (PACIFIC 4/RTOG-3515) A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-Small Cell Lung Cancer.

STU 2021.0475 Pilot Study of Ruxolitinib in the Treatment of Cancer Cachexia.

If you’re interested in a clinical trial, please talk to your doctor.

Learn more about clinical trials.

Helpful Resources